Desjardins, A., Randazzo, D., Chandramohan, V., Katherine B., P., Johnson, M. O., Threat, S., … Bigner, D. (2020). Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). In Journal of Clinical Oncology (Vol. 38, pp. 20s-20s). (virtual): American Society of Clinical Oncology. https://doi.org/10.1200/JCO.2020.38.15_suppl.2566

Desjardins, Annick, Dina Randazzo, Vidyalakshmi Chandramohan, Peters Katherine B., Margaret O. Johnson, Steve Threat, Chevelle A. Bullock, et al. “Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).” In Journal of Clinical Oncology, 38:20s-20s. American Society of Clinical Oncology, 2020. https://doi.org/10.1200/JCO.2020.38.15_suppl.2566.

Desjardins A, Randazzo D, Chandramohan, V, Katherine B. P, Johnson MO, Threat S, et al. Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). In: Journal of Clinical Oncology. American Society of Clinical Oncology; 2020. p. 20s-20s.

Desjardins, Annick, et al. “Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).” Journal of Clinical Oncology, vol. 38, no. 15s, American Society of Clinical Oncology, 2020, pp. 20s-20s. Manual, doi:10.1200/JCO.2020.38.15_suppl.2566.

Desjardins A, Randazzo D, Chandramohan, V, Katherine B. P, Johnson MO, Threat S, Bullock CA, Herndon JE, Healy P, Lipp ES, Sampson J, Friedman H, Ashley D, Bigner D. Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Journal of Clinical Oncology. American Society of Clinical Oncology; 2020. p. 20s-20s.